Prevalence, Patient Characteristics, and Pharmacological Treatment of Children, Adolescents, and Adults Diagnosed With ADHD in Sweden

Journal of Attention Disorders

Volumn 22, Issue 1, 2018, Pages 3-13

  Giacobini, MaiBritt ^a   Medin, Emma ^b,c   Ahnemark, Ewa ^d   Russo, Leo J ^e   Carlqvist, Peter ^c  

^a PRIMA Barn och Vuxenpsykiatri   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PAREXEL INTERNATIONAL   (United States)

^d Shire   (Sweden)

^e SHIRE   (United States)

Author keywords

ADHD; psychostimulants; treatment

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; COMORBIDITY; COMPLICATION; CROSS-SECTIONAL STUDY; DRUG DEPENDENCE; FEMALE; HUMAN; MALE; NEWBORN; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; REGISTER; STATISTICS AND NUMERICAL DATA; SWEDEN; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISM SPECTRUM DISORDER; CHILD; CHILD, PRESCHOOL; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; METHYLPHENIDATE; PREVALENCE; REGISTRIES; SUBSTANCE-RELATED DISORDERS; SWEDEN; YOUNG ADULT;

EID: 85038227993     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054714554617     Document Type: Article

References (44)

1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
3. Antshel K. M., Zhang-James Y., Faraone S. V., (2013). The comorbidity of ADHD and autism spectrum disorder. Expert Review of Neurotherapeutics, 13, 1117-1128.
4. Bahmanyara S., Sundström A., Kaijsera M., von Knorring A.-L., Kielera H., (2013). Pharmacological treatment and demographic characteristics of pediatric patients with attention deficit hyperactivity disorder, Sweden. European Neuropsychopharmacology, 23, 1732-1738. doi:10.1016/j.euroneuro.2013.07.009
5. Barkley R. A., Fischer M., Smallish L., Fletcher K., (2004). Young adult follow-up of hyperactive children: Antisocial activities and drug use. Journal of Child Psychology and Psychiatry, 45, 195-211.
6. Biederman J., Wilens T., Spencer T. J., (2007). Diagnosis and treatment of adults with attention-deficit/hyperactivity disorder. CNS Spectrums, 12(Suppl. 6), 1-15.
7. Cheon K. A., Ryu Y. H., Kim Y. K., Namkoong K., Kim C. H., Lee J. D., (2003). Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. European Journal of Nuclear Medicine and Molecular Imaging, 30, 306-311.
8. Dalsgaard S., Nielsen H. S., Simonsen M., (2013). Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: A Danish register-based study. Journal of Child and Adolescent Psychopharmacology, 23, 432-439.
9. Faraone S. V., Biederman J., (2005). What is the prevalence of adult ADHD? Results of a population screen of 966 adults. Journal of Attention Disorders, 9, 384-391.
10. Faraone S. V., Biederman J., Mick E., (2006). The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychological Medicine, 36, 159-165.
11. FASS, SPC. (2011a). Concerta. Retrieved from http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=20021101000311&DocTypeID=6
12. FASS, SPC. (2011b). Strattera. Retrieved from http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=20050629000022&DocTypeID=6
13. Fayyad J., de Graaf R., Kessler R., Alonso J., Angermeyer M., Demyttenaere K...Jin R., (2007). Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. British Journal of Psychiatry, 190, 402-409.
14. Kadesjo B., Gillberg C., (2001). The comorbidity of ADHD in the general population of Swedish school-age children. Journal of Child Psychology and Psychiatry, 42, 487-492.
15. Kessler R. C., Adler L., Barkley R., Biederman J., Conners C. K., Demler O...Zaslavsky A. M., (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163, 716-723.
16. Klein R. G., Mannuzza S., Olazagasti M. A., Roizen E., Hutchison J. A., Lashua E. C., Castellanos F. X., (2012). Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Archives of General Psychiatry, 69, 1295-1303.
17. Kumar R., (2008). Approved and investigational uses of modafinil: An evidence-based review. Drugs, 68, 1803-1839.
18. Landgren M., Pettersson R., Kjellman B., Gillberg C., (1996). ADHD, DAMP and other neurodevelopmental/psychiatric disorders in 6-year-old children: Epidemiology and co-morbidity. Developmental Medicine & Child Neurology, 38, 891-906.
19. Larson K., Russ S. A., Kahn R. S., Halfon N., (2011). Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics, 127, 462-470.
20. Larsson H., Asherson P., Chang Z., Ljung T., Friedrichs B., Larsson J. O., Lichtenstein P., (2013). Genetic and environmental influences on adult attention deficit hyperactivity disorder symptoms: A large Swedish population-based study of twins. Psychological Medicine, 43, 197-207.
21. Medical Products Agency. (2009). Läkemedelsbehandling av ADHD. Ny rekommendation [The Pharmaceutical treatment of ADHD. New recommendations]. Information från Läkemedelsverket, 2009(1). Retrieved from http://www.lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/ADHD-rek_webb.pdf
22. Murphy K., Barkley R. A., (1996). Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments. Comprehensive Psychiatry, 37, 393-401.
23. National Board of Health and Welfare. (2002). ADHD hos barn och vuxna. Kunskapsöversikt [Children and adults with ADHD. Review]. Retrieved from http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/10942/2002-110-16_200211017.pdf
24. National Board of Health and Welfare. (2012). Förskrivning av centralstimulerande läkemedel vid ADHD [The prescribing of stimulants for the treatment of ADHD]. Retrieved from http://www.socialstyrelsen.se/publikationer2012/2012-10-30
25. National Collaborating Centre for Mental Health. (2009). Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults (National Clinical Practice Guideline No. CG72). The British Psychological Society and the Royal College of Psychiatrists. Retrieved from https://www.nice.org.uk/guidance/cg72/resources/guidance-attention-deficit-hyperactivity-disorder-pdf
26. Nylander L., Holmqvist M., Gustafson L., Gillberg C., (2013). Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in adult psychiatry. A 20-year register study. Nordic Journal of Psychiatry, 67, 344-350.
27. Pliszka S. R., (2005). The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biological Psychiatry, 57, 1385-1390.
28. Polanczyk G., de Lima M. S., Horta B. L., Biederman J., Rohde L. A., (2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. American Journal of Psychiatry, 164, 942-948.
29. Pottegard A., Bjerregaard B. K., Glintborg D., Hallas J., Moreno S. I., (2012). The use of medication against attention deficit hyperactivity disorder in Denmark: A drug use study from a national perspective. European Journal of Clinical Pharmacology, 68, 1443-1450.
30. Preuss U., Ralston S. J., Baldursson G., Falissard B., Lorenzo M. J., Rodrigues Pereira R.,.. ADORE Study Group. (2006). Study design, baseline patient characteristics and intervention in a cross-cultural framework: Results from the ADORE study. European Child & Adolescent Psychiatry, 15(Suppl.), 4-14.
31. Region Skane. (2010). Division Barn- och Ungdomspsykiatri. Regionalt vårdprogram för barn och ungdomar med ADHD [Department for Children and Adolescent Psychiatry. Regional treatment program for children and adolescents with ADHD]. Retrieved from http://www.skane.se/Public/psykiatri_skane/bup/vardprogram/Vardprogram-for-barn-och-ungdomar-med-ADHD.pdf
32. Rosler M., Casas M., Konofal E., Buitelaar J., (2010). Attention deficit hyperactivity disorder in adults. World Journal of Biological Psychiatry, 11, 684-698.
33. Simon V., Czobor P., Balint S., Meszaros A., Bitter I., (2009). Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. British Journal of Psychiatry, 194, 204-211.
34. Statistiska centralbyrån. (2013). Statistikdatabasen: Folkmängd. Region: Riket. Tid: 2006-2011. [Database for statistics: Population. Region: Entire nation. Timepoint: 2006-2011] Retrieved from http://www.scb.se/Pages/SSD/SSD_TreeView____340478.aspx?ExpandNode=BE/BE0101
35. Stiftelsen nätverk för läkemedelsepidemiologi. (2012). Läkemedel vid ADHD m.m. i Sverige 2006-2011 [Pharmaceuticals used to treat ADHD in Sweden]. Retrieved from http://www.nepi.net/120515-ADHDlakemedel.htm
36. Suren P., Bakken I. J., Lie K. K., Schjølberg S., Aase H., Reichborn-Kjennerud T...Stoltenberg C., (2013). Differences across counties in the registered prevalence of autism, ADHD, epilepsy and cerebral palsy in Norway. Tidsskrift for Den norske Legeforening, 133, 1929-1934.
37. Teva Pharma B.V., SPC. (2013). Modiodal®. Retrieved from http://www.fass.se/LIF/product?12&userType=0&nplId=20011005000203&docType=6
38. TLV. (2013). Beslut. Sök i databasen. ATC kod: N06BA [Decision. Database search, ATC code: N06BA]. Retrieved from http://www.tlv.se/beslut/sok/lakemedel/?code=N06BA&st=Standard
39. Wettermark B., Hammar N., Fored C. M., Leimanis A., Otterblad Olausson P., Bergman U...Rosén M., (2007). The new Swedish prescribed drug register—Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology & Drug Safety, 16, 726-735.
40. Wilens T. E., Faraone S. V., Biederman J., (2004). Attention-deficit/hyperactivity disorder in adults. Journal of the American Medical Association, 292, 619-623.
41. Willcutt E. G., (2012). The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics, 9, 490-499.
42. World Health Organization. (2007). International Classification of Diseases, Tenth Edition (ICD-10): Mental and behavioural disorders (F00-F99). Retrieved from http://apps.who.int/classifications/apps/icd/icd10online2007/
43. Zetterqvist J., Asherson P., Halldner L., Langstrom N., Larsson H., (2013). Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: Total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatrica Scandinavica, 128, 70-77.
44. Zoega H., Furu K., Halldorsson M., Thomsen P. H., Sourander A., Martikainen J. E., (2011). Use of ADHD drugs in the Nordic countries: A population-based comparison study. Acta Psychiatrica Scandinavica, 123, 360-367.